ID

16252

Description

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00166543

Link

https://clinicaltrials.gov/show/NCT00166543

Keywords

Versions (1)
  1. 7/7/16 7/7/16 -
Uploaded on

July 7, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer NCT00166543

English

Eligibility Breast Cancer NCT00166543

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
postmenopausal females
Description

Postmenopausal state

Data type

boolean

Alias
UMLS CUI [1]
C0232970
histologically or cytologically confirmed diagnosis of breast carcinoma
Description

Breast Carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0678222
locally advanced or locally recurrent inoperable or metastatic breast carcinoma with documented disease progression
Description

Locally advanced breast cancer | Breast cancer recurrent Locally Inoperable | Carcinoma breast stage IV | Disease Progression

Data type

boolean

Alias
UMLS CUI [1]
C3495949
UMLS CUI [2,1]
C0278493
UMLS CUI [2,2]
C1517927
UMLS CUI [2,3]
C0205187
UMLS CUI [3]
C0278488
UMLS CUI [4]
C0242656
has laboratory documentation of positive estrogen receptor (er) and/or progesterone receptor (pgr) status, and has responded to the standard first or second line hormonal anti-tumor therapy given
Description

Estrogen Receptor and/or Progesterone Receptor Positive | Response to Cancer hormonal therapy First line | Response to Cancer hormonal therapy Second line

Data type

boolean

Alias
UMLS CUI [1]
C3640067
UMLS CUI [2,1]
C0521982
UMLS CUI [2,2]
C0877050
UMLS CUI [2,3]
C1708063
UMLS CUI [3,1]
C0521982
UMLS CUI [3,2]
C0877050
UMLS CUI [3,3]
C1710038
has received and whose disease progressed after one or two prior systemic hormonal anti-tumor therapies
Description

Cancer hormonal therapy Systemic | Disease Progression

Data type

boolean

Alias
UMLS CUI [1,1]
C0877050
UMLS CUI [1,2]
C0205373
UMLS CUI [2]
C0242656
performance status of greater than or equal to 2 on the zubrod scale
Description

Zubrod Performance Status

Data type

boolean

Alias
UMLS CUI [1]
C3714786
predicted life expectancy of greater than or equal to 12 weeks
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
must give written informed consent
Description

Informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
measurable disease according to the response evaluation criteria in solid tumors (recist) criteria
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
absolute granulocyte count of greater than 1,500/meql, platelet count greater than 75,000/meql, and a hemoglobin of greater than 10 g/dl
Description

Absolute neutrophil count | Platelet Count measurement | Hemoglobin

Data type

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0019046
adequate liver and renal function as defined by a bilirubin of less than 1.5 times the upper limit of normal and a creatinine of less than 1.5 times the upper limit of normal
Description

Liver function | Renal function | Serum total bilirubin measurement | Creatinine measurement, serum

Data type

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
UMLS CUI [3]
C1278039
UMLS CUI [4]
C0201976
transaminases must be less than 2.5 times the upper limit of normal except for patients with liver metastases who may have transaminases less than 5 times the upper limit of normal.
Description

Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Secondary malignant neoplasm of liver

Data type

boolean

Alias
UMLS CUI [1]
C0201836
UMLS CUI [2]
C0201899
UMLS CUI [3]
C0494165
the patient has recovered from all previous anti-cancer treatment related to toxicities to at least grade 1.
Description

cancer treatment Due to Toxicities | Patient recovered

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C0600688
UMLS CUI [2]
C1115804
all previous investigational drugs must be stopped at least four weeks before commencement of treatment with tas-108.
Description

Investigational New Drugs Previous Stop | TS 108 Start

Data type

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0205156
UMLS CUI [1,3]
C0850893
UMLS CUI [2,1]
C1435232
UMLS CUI [2,2]
C0439659
Back to the top of the page

Similar models

Eligibility Breast Cancer NCT00166543

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state
Item
postmenopausal females
boolean
C0232970 (UMLS CUI [1])
Breast Carcinoma
Item
histologically or cytologically confirmed diagnosis of breast carcinoma
boolean
C0678222 (UMLS CUI [1])
Locally advanced breast cancer | Breast cancer recurrent Locally Inoperable | Carcinoma breast stage IV | Disease Progression
Item
locally advanced or locally recurrent inoperable or metastatic breast carcinoma with documented disease progression
boolean
C3495949 (UMLS CUI [1])
C0278493 (UMLS CUI [2,1])
C1517927 (UMLS CUI [2,2])
C0205187 (UMLS CUI [2,3])
C0278488 (UMLS CUI [3])
C0242656 (UMLS CUI [4])
Estrogen Receptor and/or Progesterone Receptor Positive | Response to Cancer hormonal therapy First line | Response to Cancer hormonal therapy Second line
Item
has laboratory documentation of positive estrogen receptor (er) and/or progesterone receptor (pgr) status, and has responded to the standard first or second line hormonal anti-tumor therapy given
boolean
C3640067 (UMLS CUI [1])
C0521982 (UMLS CUI [2,1])
C0877050 (UMLS CUI [2,2])
C1708063 (UMLS CUI [2,3])
C0521982 (UMLS CUI [3,1])
C0877050 (UMLS CUI [3,2])
C1710038 (UMLS CUI [3,3])
Cancer hormonal therapy Systemic | Disease Progression
Item
has received and whose disease progressed after one or two prior systemic hormonal anti-tumor therapies
boolean
C0877050 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
Zubrod Performance Status
Item
performance status of greater than or equal to 2 on the zubrod scale
boolean
C3714786 (UMLS CUI [1])
Life Expectancy
Item
predicted life expectancy of greater than or equal to 12 weeks
boolean
C0023671 (UMLS CUI [1])
Informed consent
Item
must give written informed consent
boolean
C0021430 (UMLS CUI [1])
Measurable Disease
Item
measurable disease according to the response evaluation criteria in solid tumors (recist) criteria
boolean
C1513041 (UMLS CUI [1])
Absolute neutrophil count | Platelet Count measurement | Hemoglobin
Item
absolute granulocyte count of greater than 1,500/meql, platelet count greater than 75,000/meql, and a hemoglobin of greater than 10 g/dl
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
Liver function | Renal function | Serum total bilirubin measurement | Creatinine measurement, serum
Item
adequate liver and renal function as defined by a bilirubin of less than 1.5 times the upper limit of normal and a creatinine of less than 1.5 times the upper limit of normal
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Secondary malignant neoplasm of liver
Item
transaminases must be less than 2.5 times the upper limit of normal except for patients with liver metastases who may have transaminases less than 5 times the upper limit of normal.
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0494165 (UMLS CUI [3])
cancer treatment Due to Toxicities | Patient recovered
Item
the patient has recovered from all previous anti-cancer treatment related to toxicities to at least grade 1.
boolean
C0920425 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0600688 (UMLS CUI [1,3])
C1115804 (UMLS CUI [2])
Investigational New Drugs Previous Stop | TS 108 Start
Item
all previous investigational drugs must be stopped at least four weeks before commencement of treatment with tas-108.
boolean
C0013230 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0850893 (UMLS CUI [1,3])
C1435232 (UMLS CUI [2,1])
C0439659 (UMLS CUI [2,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial